About Miguel Garcia-Guzman
Form D filings for Valora Therapeutics in 2024 list Miguel Garcia-Guzman as chief executive officer and director.
Form D filings also name Miguel Garcia-Guzman as a director at Rakuten Medical.
Miguel Garcia-Guzman first appears on SEC filings in 2015.
Experience
This experience comes from Miguel Garcia-Guzman's profile and from SEC filings. For roles taken from filings, the years are when the filings name Miguel Garcia-Guzman in the role, so the role may have started earlier or lasted longer.
AI
Arisan Therapeutics, Inc Current
Board Member
2021 – Present
Rakuten Medical, Inc. Current
Director
2010 – Present · San Diego, CA
Develops and commercializes cell-targeting cancer treatments for patients.
QU
Qureator
Scientific Advisor
2023 – 2024
RA
Rakuten Aspyrian
Founder, President, and Chief Scientific Officer
2010 – 2015
VP
Vertex Pharmaceuticals
Senior Scientist, Associated Director, Research Fellow
2000 – 2010
AI
Arcaris Therapeutics Inc
Senior Scientist
1999 – 2000
SI
Sanford Burnham Prebys Medical Discovery Institute
Research Investigator
1997 – 1999
MM
Max Planck Institute Experimental Medicine
Research Investigator
1994 – 1997
Key Colleagues at Startups
The people Miguel Garcia-Guzman works with at each company, as listed on that company's latest Form D.
Rakuten Medical, Inc. · Form D, Oct 6, 2026
MM
Minami Maeda
Executive officer
DC
David Chao
Director
HM
Hiroshi Mikitani
Executive Chairman
HM
Hiroshi Mori
Director
KT
Ken Takeshita
Director
CW
Christophe Weber
Vice Chairman
NN
Nitin Nohria
Lead Independent Director
EK
Eiichi Kaga
Director
MD
Mazen Darwazeh
Director
TP
Tiffany Piecewicz
General Counsel & Corporate Secretary
Abhijit Bhatia
Chief Operating Officer (COO)
Toshiaki Suzuki
Chief Surgical Officer
SS
Suzane San
Chief People Officer & U.S. Divisional Officer
Hiroyuki Kodama
Chief Product Officer (CPO)
Louise Chang
Executive officer
Amy Thorne
Chief Scientific Officer
AM
Anthony Manibusan
Chief Technical Officer
Hassan Danesi
Chief Medical Officer (CMO)
Valora Therapeutics, Inc. · Form D, Jul 24, 2024
SH
Stefan Heller
Director
SM
Sanford Madigan
Director